

DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

<u>L4</u>	(transplant\$ or graft\$)same (alkylating or bulsulfan)same (after or post)	4	<u>L4</u>
-----------	---	---	-----------

DB=PGPB,USPT; PLUR=YES; OP=ADJ

<u>L3</u>	(transplant\$ or graft\$)same (alkylating or bulsulfan)same (after or post)	56	<u>L3</u>
-----------	---	----	-----------

<u>L2</u>	L1 and (transplant\$ or graft\$) and (alkylating or bulsulfan)	8	<u>L2</u>
-----------	--	---	-----------

<u>L1</u>	larsen.in.	3247	<u>L1</u>
-----------	------------	------	-----------

END OF SEARCH HISTORY

Set Items Description

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin 5,73,15,399

21nov05 08:31:25 User208760 Session D2658.2

\$0.00 0.102 DialUnits File410

\$0.00 Estimated cost File410

\$0.02 TELNET

\$0.02 Estimated cost this search

\$0.54 Estimated total session cost 0.250 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2005/Nov W2

(c) 2005 BIOSIS

File 73:EMBASE 1974-2005/Nov 21

(c) 2005 Elsevier Science B.V.

File 15:ABI/Inform(R) 1971-2005/Nov 19

(c) 2005 ProQuest Info&Learning

File 399:CA SEARCH(R) 1967-2005/UD=14322

(c) 2005 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement.

Alert feature enhanced for multiple files, etc. See HELP ALERT.

Set Items Description

? e au=larsen christian ?

Ref Items Index-term

E1 6 AU=LARSEN CHRISTEN P

E2 5 AU=LARSEN CHRISTIAN

E3 0 *AU=LARSEN CHRISTIAN ?

E4 7 AU=LARSEN CHRISTIAN G

E5 1 AU=LARSEN CHRISTIAN GRONBHOJ

E6 15 AU=LARSEN CHRISTIAN GRONHOJ

E7 1 AU=LARSEN CHRISTIAN J

E8 1 AU=LARSEN CHRISTIAN JACQUES

E9 1 AU=LARSEN CHRISTIAN KLEIN

E10 61 AU=LARSEN CHRISTIAN P

E11 3 AU=LARSEN CHRISTIAN RIFBJERG

E12 35 AU=LARSEN CHRISTIAN-JACQUES

Enter P or PAGE for more

? s e10

S1 61 AU='LARSEN CHRISTIAN P'

? s s1 and (alkylating or bulsulfan?)

61 S1

29292 ALKYLATING

17 BULSULFAN?

S2 0 S1 AND (ALKYLATING OR BULSULFAN?)

? s (alkylating or bulsulfan?) (20n) (transplant? or graft?) (20n)post or afer)

>>>Unmatched parentheses

? s (alkylating or bulsulfan?) (20n) (transplant? or graft?) (20n) (post? or afer)

>>>File 5 processing for POST? stopped at POSTDETRAINING

>>>File 73 processing for POST? stopped at POSTDAMAGE

>>>File 15 processing for POST? stopped at POSTOUTBREAK

>>>File 399 processing for POST? stopped at POSTOXIDATION

29292 ALKYLATING

17 BULSULFAN?

1259757 TRANSPLANT?

430248 GRAFT?

904039 POST?

1811 AFER

S3 15 (ALKYLATING OR BULSULFAN?) (20N) (TRANSPLANT? OR

GRAFT?) (20N) (POST? OR AFER)

? rd s3

...completed examining records
S4 9 RD S3 (unique items)
? t s4/3/all

4/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0014998922 BIOSIS NO.: 200400369711
Autologous stem cell **transplantation** using modified TAM or
combination of triple-**alkylating** agents conditioning regimens as
one of the **post**-remission treatments in patients with adult acute
myeloid leukemia in first complete remission
AUTHOR: Kim H J; Min W S (Reprint); Eom K S; Park S J; Park Y H; Kim D W;
Lee J W; Park C W; Kim C C
AUTHOR ADDRESS: Coll MedCatholic Hemopoiet Stem Cell Transplantat CtrDept
Internal Med,Div Hematol, Catholic Univ Korea, Seoul, 150713, South Korea
**South Korea
AUTHOR E-MAIL ADDRESS: wsmin@catholic.ac.kr
JOURNAL: Bone Marrow Transplantation 34 (3): p215-220 August 2004 2004
MEDIUM: print
ISSN: 0268-3369 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0014780200 BIOSIS NO.: 200400146861
Myelodysplastic CD34+ clones can be detected by fluorescent in situ
hybridization in the stem cell harvest of myeloma patients who develop
treatment-related myelodysplastic syndrome following autologous
transplantation.
AUTHOR: Thertulien Raymond (Reprint); Ojha Rohit (Reprint); Zangari
Maurizio (Reprint); Fassas Athanasios (Reprint); Anaissie Elias J
(Reprint); Lee Choon-Kee (Reprint); vanRhee Frits (Reprint); Barlogie
Bart (Reprint); Tricot Guido J (Reprint)
AUTHOR ADDRESS: Myeloma Institute for Research and Therapy, University of
Arkansas for Medical Sciences, 4301 W. Markham, Slot 776, Little Rock,
AR, USA**USA
JOURNAL: Blood 102 (11): p424a November 16, 2003 2003
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of
Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

4/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0014039869 BIOSIS NO.: 200200633380
Semen analysis following allogeneic bone marrow transplantation. Additional
data for evidence-based counselling
AUTHOR: Anserini P (Reprint); Chiodi S; Spinelli S; Costa M; Conte N;
Copello F; Bacigalupo A
AUTHOR ADDRESS: Centro Infertilita, Dipartimento di Ostetricia e
Ginecologia, Universita di Genova, Ospedale San Martino, Pad 1, Largo
Benzi, 16132, Genova, Italy, Italy**Italy
JOURNAL: Bone Marrow Transplantation 30 (7): p447-451 October 2002 2002

2002
MEDIUM: print
ISSN: 0268-3369
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0013133644 BIOSIS NO.: 200100305483
Successful treatment of scleromyxedema with autologous peripheral blood
stem cell transplantation
AUTHOR: Hogan William J (Reprint); Lacy Martha Q (Reprint); Schroeter
Arnold L; Litzow Mark R (Reprint); Gertz Morie A (Reprint)
AUTHOR ADDRESS: Division of Hematology, Mayo Medical Center, Rochester, MN,
USA**USA
JOURNAL: Blood 96 (11 Part 2): p370b November 16, 2000 2000
MEDIUM: print
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of
Hematology San Francisco, California, USA December 01-05, 2000; 20001201
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

4/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0011994025 BIOSIS NO.: 199900253685
Administration and pharmacokinetics of high-dose cyclophosphamide with
hemodialysis support for allogeneic bone marrow transplantation in acute
leukemia and end-stage renal disease
AUTHOR: Perry J J (Reprint); Fleming R A; Rocco M V; Petros W P; Bleyer A J
; Radford J E Jr; Powell B L; Hurd D D
AUTHOR ADDRESS: Section of Hematology/Oncology, Department of Internal
Medicine, Wake Forest University School of Medicine, Medical Center
Boulevard, Winston-Salem, NC, 27157, USA**USA
JOURNAL: Bone Marrow Transplantation 23 (8): p839-842 April 2, 1999 1999
MEDIUM: print
ISSN: 0268-3369
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0011688543 BIOSIS NO.: 199800482790
The role of thiotepea in autologous bone marrow transplantation for acute
leukemia
AUTHOR: Nagler Arnon (Reprint); Finlander Rosales; Or Reuven; Naparstek
Elizabeth; Varadi Gabor; Slavin Shimon
AUTHOR ADDRESS: Dep. Bone Marrow Transplant., Hadassah Univ. Hosp.,
Jerusalem, Israel**Israel
JOURNAL: Leukemia Research 22 (11): p991-995 Nov., 1998 1998
MEDIUM: print
ISSN: 0145-2126
DOCUMENT TYPE: Article
RECORD TYPE: Abstract

LANGUAGE: English

4/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0010003328 BIOSIS NO.: 199598471161
Relapse of multiple myeloma after autologous transplantation: Survival
after salvage therapy
AUTHOR: Tricot G (Reprint); Jagannath S; Vesole D H; Crowley J; Barlogie B
AUTHOR ADDRESS: Div. Hematol./Oncol., Univ. Arkansas Med. Sci., 4301 West
Markham, Slot 508, Little Rock, AR 72205, USA**USA
JOURNAL: Bone Marrow Transplantation 16 (1): p7-11 1995 1995
ISSN: 0268-3369
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/8 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2005 Elsevier Science B.V. All rts. reserv.

06664232 EMBASE No: 1996329113
Preceding standard therapy is the likely cause of MDS after
autotransplants for multiple myeloma
Govindarajan R.; Jagannath S.; Flick J.T.; Vesole D.H.; Sawyer J.;
Barlogie B.; Tricot G.
Division of Hematology/Oncology, Univ. Arkansas for Medical Sciences,
4301 West Markham, Slot 508, Little Rock, AR 72205 United States
British Journal of Haematology (BR. J. HAEMATOL.) (United Kingdom)
1996, 95/2 (349-353)
CODEN: BJHEA ISSN: 0007-1048
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/9 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2005 Elsevier Science B.V. All rts. reserv.

02738602 EMBASE No: 1984057561
Malignant lesions in rheumatoid arthritis; the influence of treatment
with cyclophosphamide
Baltus J.A.M.; Boersma J.W.; Vandenbroucke J.P.
Afd. Reumatologie, Gemeente Ziekenhuis, Arnhem Netherlands
Nederlands Tijdschrift voor Geneeskunde (NED. TIJDSCHR. GENEESKD.) (
Netherlands) 1984, 128/5 (205-209)
CODEN: NETJA
DOCUMENT TYPE: Journal
LANGUAGE: DUTCH SUMMARY LANGUAGE: ENGLISH
? t s4/kwic/all
>>>KWIC option is not available in file(s): 399

4/KWIC/1 (Item 1 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

Autologous stem cell **transplantation** using modified TAM or
combination of triple-**alkylating** agents conditioning regimens as
one of the **post**-remission treatments in patients with adult acute
myeloid leukemia in first complete remission

4/KWIC/2 (Item 2 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

...ABSTRACT: to the clinical presentation of t-MDS. Our data support the hypothesis that conventional pre-**transplant alkylating** chemotherapy is the major culprit for the development of **post-transplant** MDS, which may be accentuated by the stress of hematopoietic recovery. Our findings suggest that the risk of *****post***** - **transplant** MDS may be decreased by limiting pretransplant induction treatment to <6 mos and limiting exposure...

4/KWIC/3 (Item 3 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

...ABSTRACT: of patients, whereas it was consistently severely impaired in patients who received irradiation or two *****alkylating***** agents. Following CY, spermatogenesis recovery was observed in 60% of patients tested 1 year **post transplant** and it was accomplished within the third year in 80% of cases. Following CY+TBI/TAI recovery of spermatogenesis never occurred before the 4th year **post transplant** and was demonstrated as late as 9 years in one patient who was azoospermic 1...

4/KWIC/4 (Item 4 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

...ABSTRACT: Neither patient has demonstrated clinical or laboratory evidence of relapse at 19 and 8 months **post transplant** respectively. Conclusion We believe that autologous hematopoietic progenitor cell **transplantation** should be considered in patients with scleromyxedema. It is prudent to consider stem-cell harvest before prolonged exposure to melphalan, because **alkylating** agents can affect the quantity and quality of stem-cell harvests.

4/KWIC/5 (Item 5 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

...ABSTRACT: and its metabolites. Pharmacokinetic analyses indicated that the elimination of high-dose CY and its **alkylating** metabolites is impaired in ESRD but is cleared with hemodialysis. The patient's early **post-transplant** course was uncomplicated, and WBC and platelet engraftment occurred by day +22. Bone marrow examination...

4/KWIC/6 (Item 6 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

ABSTRACT: **Post-transplant** leukemic relapse remains the major problem following autologous bone marrow *****transplantation***** (ABMT). One possible approach to reducing the relapse rate is to intensify pretransplant conditioning. Thiotepa (TTP) is an *****alkylating***** agent that has been used mainly in breast and ovarian cancer with 20-50% responses...

4/KWIC/7 (Item 7 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

...ABSTRACT: lack of progress with standard chemotherapy and the presence of a dose response effect for **alkylating** agents, autotransplantation is performed with increasing frequency for multiple myeloma (MM). However, sustained relapse-free...

...patients who had relapsed following autotransplantation, in order to evaluate the efficacy of further therapy. *****Post***** - *****transplant***** salvage treatment consisted of either standard dose therapy (53) or transplantation with an intensive preparative...

4/KWIC/8 (Item 1 from file: 73)
DIALOG(R)File 73:(c) 2005 Elsevier Science B.V. All rts. reserv.

...group 2) with more prolonged conventional therapy ($P = 0.0001$). All seven patients developing MDS **post-transplantation** belonged to group 2 ($P = 0.02$); the median durations from initial therapy and first **transplant** were 66 months (range 38-86) and 24 months (range 9-39), respectively. Our findings provide evidence that prolonged standard-dose **alkylating** agent therapy prior to transplantation, rather than autotransplant-supported myeloablative treatment, is associated with development...

4/KWIC/9 (Item 2 from file: 73)
DIALOG(R)File 73:(c) 2005 Elsevier Science B.V. All rts. reserv.

...of the malignant tumours that have been described in connection with immunosuppression. This category included *****post*** - ***transplantation***** patients and patients with other indications for cytotoxic therapy. The *****alkylating***** agents emerged as a particularly pronounced risk factor. The same holds true of RA, and...
?